The U.S. Department of Veterans Affairs Awards Contract to Evofem Biosciences for Phexxi®
December 03 2020 - 07:00AM
SAN DIEGO, Dec. 3, 2020 /PRNewswire/ -- Evofem Biosciences, Inc., (NASDAQ: EVFM) today announced that the U.S. Department of Veterans Affairs (VA) has awarded the Company a contract for the purchase of Phexxi® (lactic acid, citric acid and potassium bitartrate) for a five-year period beginning December 15, 2020.
(PRNewsfoto/Evofem Biosciences, Inc.)
Saundra Pelletier, CEO of Evofem Biosciences, said, "This award is an important milestone in our ongoing effort to create the broadest access to Phexxi for all patients. We have achieved coverage for 55% of commercial lives in the U.S., including nearly 8 million lives at zero copay, and are very pleased to expand into government programs. We look forward to providing Phexxi to the women who are a part of this program, which includes VA, Tricare, Department of Defense, Coast Guard and Indian Health Services and under which approximately 12 million lives will have access to Phexxi."
This award was recently listed on the U.S. government's SAM website.
About the Department of Veterans Affairs Federal Supply Schedule (VA FSS)
Under delegated authority by GSA, the VA manages multiple award contracts for medical equipment, supply, pharmaceutical, and service Schedule programs. With over $14 billion in sales, the VA FSS Service supports the healthcare requirements of the VA and other federal government agencies by providing Federal customers with access to over 1 million state-of-the-art commercial products and services.
==========================================================
rumor from yesterday
Evofem Biosciences Shares Tick Slightly Higher Following Circulation Of Beta.Sam.gov Notice For ~$7.6M Contract From Dept. Of Veterans Affairs
